Aims Myocardial function is severely compromised during sepsis. Several underlying mechanisms have been proposed. The innate immune system, i.e. Toll-like receptor (TLR) 2 and 4, significantly contributes to cardiac dysfunction. Little is known regarding TLR9 and its pathogenic ligand bacterial DNA in the myocardium. We therefore studied the role of TLR9 in myocardial inflammation and cardiac contractility. Methods and results Wild-type (WT, C57BL/6) and TLR9-deficient (TLR9-D) mice and isolated cardiomyocytes were challenged with synthetic bacterial DNA (CpG-ODN). Myocardial contractility as well as markers of inflammation/signalling were determined. Isolated cardiomyocytes incorporated fluorescence-marked CpG-ODN. In WT mice, CpG-ODN caused a robust response in hearts demonstrated by increased levels of tumour necrosis factor (TNF-a), interleukin (IL)-1b, IL-6, inducible nitric oxide synthase (iNOS), and nuclear factor kB activity. This inflammatory response was absent in TLR9-D mice. Under similar conditions, contractility measurements of isolated ventricular cardiomyocytes demonstrated a TLR9-dependent loss of sarcomeric shortening after CpG-ODN exposure. This observation was iNOS dependent as the application of a specific iNOS inhibitor reversed sarcomeric shortening to normal levels. Conclusion Our data suggest that bacterial DNA contributes to myocardial cytokine production and loss of cardiomyocyte contractility via TLR9.
Introduction
Sepsis represents a significant health problem in the western world. This disease is the leading cause of death in noncoronary intensive care units, with a mortality rate ranging from 20 to 80% of severely affected patients. 1, 2 In the United States, the incidence of sepsis has risen from 160 000 cases in 1979 to 700 000 in 2000 (an increase of 13.7% per year). 3 Recent data estimate that .150 000 patients suffer from sepsis each year in Germany. 4 Cardiovascular dysfunction is a serious complication occurring in 40% of patients with sepsis, 5 increasing mortality from 20-70%. 6 During experimental sepsis high levels of tumour necrosis factor (TNF-a) and interleukin (IL)-1b are detectable in the heart. 7, 8 There is consent that these cytokines severely compromise cardiac function during human sepsis. 9, 10 Altered cardiac nitric oxide (NO) production also plays an important role for cardiac dysfunction during sepsis. 11 However, the proximal events that trigger and sustain the expression in the heart are not fully understood. The identification of toll-like receptors (TLRs) has been a major advance in the understanding of the pathogenesis of septic shock. 12 To date, 13 TLRs (TLR1-13) have been described; TLR2 and TLR4 are the best-characterized receptors so far. 13, 14 We have recently reported that TLR4 and CD14 mediate the induction of cardiac TNF-a, IL-1b, and NO following lipopolysaccharide (LPS) challenge. [15] [16] [17] More important, mice deficient for either TLR4 or CD14 are protected against LPS-induced left ventricular dysfunction. 16, 18 In addition, other virulence factors that act as TLR ligands have been discussed in the pathophysiology of myocardial dysfunction. [19] [20] [21] These studies provided new insights into the pathogenesis of sepsis-induced cardiac depression; however, the full picture needs to be elucidated.
Bacterial DNA (CpG-ODN) can initiate an innate immune response via TLR9 potentially leading to septic shock, 22, 23 septic arthritis, 24 or meningitis. 25 Bacterial CpG motifs are un-methylated cytosine-phosphate-guanine (CpG) dinucleotides and are predominantly prevalent in bacterial DNA, but not in mammalian DNA. 26 The effects of bacterial DNA can be mimicked by synthetic oligonucleotides via the same receptor system. 27, 28 Little is known about the role of TLR9 in the myocardium, but constitutive expression levels have been detected in mouse hearts. 29, 30 We therefore investigated whether TLR9 activation via CpG-ODN contributes to cardiac depression using in vivo and in vitro models.
Methods

Animals
TLR9-deficient (TLR9-D) mice, kindly provided by Professor Shizuo Akira, Osaka University, Osaka, Japan, 27 back-crossed to a C57BL/6 background, were handled according to the principles of laboratory animal care (NIH publication no: 85-23, revised 1996) and experimental procedures were approved by the German government ethical and research boards (50.203.2-BN 43, 28/01).
CpG-ODN challenge
Mice were intraperitoneally (i.p.) sensitized with 1 mg/kg D-galactosamine (D-GalN; Roth, Karlsruhe, Germany; in control experiments D-GalN alone did not induce an inflammatory response; data not shown). Thirty minutes later, mice received i.p. 1 nmol/g CpG-ODN (1668-Thioat; containing a 'CG-motif': 5 0 -TCC-ATG-ACG-TTC-CTG-ATG-CT; TibMolBiol, Berlin, Germany). According to the manufacturer, the oligonucleotides are endotoxin-free because they were synthetically synthesized like primers for polymerase chain reactions (PCR) with the difference of a thioat backbone. Oligonucleotides were dissolved in endotoxin-free water (Aqua ad Injectabili). Other groups have used these oligonucleotides finding no indication of LPS contamination. [31] [32] [33] The CG sequence in a concentration of 1 nmol/g was chosen according to earlier publications. 22, 23, 27 The selected dose was sufficient to induce clinical symptoms of sepsis. Both groups used 20 nmol per mouse, because the average body weight of their experimental animals was around 20 g. We have administered 1 nmol/g CpG-ODN in order to guarantee a weight-independent stimulatory dose. Preliminary data examining different concentrations of CpG-ODN (0-50 nmol) on cytokine expression in pulmonary tissue demonstrate a concentration-dependent increase up to 20 nmol. At 50 nmol no further increase was observed indicating that 20 nmol is a saturating concentration with respect to cytokine induction (data not shown). Two other non-CG containing oligonucleotides ODN 1612 (5 0 -GCT-AGA-TGT-TAG-CGT5) and ODN H154 (5 0 -CCT-CAA-GCT-TGA-GGG-G-3) 34 or 1 mL/kg saline were used as negative controls. Hearts were prepared immediately after sacrificing the animals. Beating hearts were transferred into cold sterile potassium buffer solution (PBS) and allowed to beat spontaneously until no more blood was pumped out of the aortic root, snap-frozen in liquid nitrogen, and kept at 2808C until assayed.
Real-time polymerase chain reaction for TRL9
Total RNA from whole murine hearts was isolated with the guanidinum thiocyanate method. 35 RNA concentration was determined by absorbance at 260 nm. Until further processing, RNA was dissolved in 100 ml of RNase-free water and stored at 2808C. Reverse transcription was performed using QIAGEN Omniscript Reverse Transcription kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. One microgram RNA was used in 20 ml reaction mixtures containing 2 ml 10Â reverse transcription buffer, 2 ml dNTP mixture (5 mM of each dNTP), 1 ml Omniscript Reverse Transcriptase, and 2 ml oligo-dT primers. The specific pre-made TaqManwGene Expression Assays (Applied Biosystems, Foster City, CA, USA) for murine TLR9 (Mm00446193_m1, amplicon length: 60 bp) and murine GAPDH (Mm99999915_g1) as housekeeping gene were used in this study. Real-time PCR (RT-PCR) was performed according to the manufacturer's protocol. Hundred nanogram of single-stranded cDNA was mixed with supplied 2Â TaqMan Universal Master Mix (PN 4304437, Applied Biosystems) and 0.5 ml of TaqManwGene Expression Assay to a final volume of 10 ml in a 384-well optical reaction plate. Each sample underwent 40 cycles of amplification in a 384-well optical reaction plate on an ABI PRISMw Sequence Detection Systems. Relative quotients (RQ) of TLR9 gene expression comparing control mice with stimulated mice at different time points were calculated with SDS Software 2.2 (Applied Systems, Foster City, CA, USA). RQ results were analysed with GraphPad Prism 4.05 (GraphPad Software, San Diego, USA).
Western blot analysis for TLR9
Frozen tissue was lysed in ice-cold buffer (150 mM NaCl, 50 mM TrisHCl, pH 7.4, 1 mM EDTA, 5 mg/mL Leupeptin, 5 mg/mL aprotinin, 1 mM PMSF, 0.1% SDS, 1% sodium deoxycholate, 1% Triton X-100) as previously published. 36 After brief centrifugation (16 800g), supernatants were removed, total protein was determined (bicinchoninic acid method), separated by SDS-PAGE and blotted onto nitrocellulose membranes. The blots were incubated with anti-TLR9-antibody (1:1000, IMG-431, Imgenex, San Diego, CA, USA) at 48C overnight. Horseradish peroxidase-conjugated anti-rabbit secondary antibody (1:3000, GE Healthcare, Braunschweig, Germany) was used. Signals were visualized by enhanced chemiluminescence.
Polymerase chain reaction for iNOS
Whole hearts from wild-type (WT) and TLR9-D mice were collected 4 h after stimulation. RNA was isolated with the Perfect RNA Eukaryotic Mini kit (Eppendorf, Hamburg, Germany). First-strand cDNA was synthesized with the Omniscript Reverse Transcriptase kit (Qiagen). The single-stranded cDNA was amplified by PCR. Inducible nitric oxid synthase (iNOS) primer sequences, PCR conditions, and amplification length were defined as follows: 5 0 -ACA ACG TGA AGA AAA CCC CTT GTG-3 0 (sense) and 5 0 -ACA GTT CCG AGC GTC AAA GAC C-3 0 (anti-sense); 30 s at 948C, 30 s at 578C, and 60 s at 728C; 35 cycles, and 557 bp. The same cDNA was used for b-actin amplification [5 0 -ATG GAT GAC GAT ATC GCT-3 0 (sense) and 5 0 -ATG AGG TAG TCT GTC AGG T-3 0 (anti-sense); 45 s at 948C, 30 s at 568C, and 60 s at 728C; 30 cycles; and 570 bp] to confirm that equal amounts of RNA were transcribed. For semi-quantitative analysis, PCR cycles were chosen within the exponential phase of the cDNA amplification. Equal amounts of RT-PCR products were separated on 2% agarose gel. Optical densities of ethidium bromide-stained DNA bands were quantified. The results were expressed as iNOS/ b-actin OD ratios.
Electrophoretic mobility shift assay
Myocardial protein extracts were prepared with NE-PER TM Nuclear and Cytoplasmic Extraction Reagents (Perbio, Bonn, Germany) according to the manufacturer's protocol. 37 Nuclear factor kB (NFkB) oligonucleotides were end-labelled with [g-32P] ATP. Binding reactions (25 mL total) were performed with nuclear extracts and the specificity of the DNA-protein binding was determined by cold chase analysis as well as with supershift assays. Nuclear extracts were incubated with 2 mg of polyclonal anti-p50 (sc-114x) or anti-p65 (sc-109x) antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). DNA-protein complexes were electrophoresed, gels were TRL9 and myocardial inflammationdried, exposed overnight, and scanned with a phosphoimager (FLA3000, Fujifilm Europe, Düsseldorf, Germany).
Ribonuclease protection assay
Myocardial RNA was extracted with the guanidinium thiocyanate method. 35 The mRNA-expression was determined with a RNase protection assay system as earlier described in detail. 15 
Enzyme-linked immunosorbent assay
Whole hearts were dispersed with an Ultra-Turrax TP18-10 (IKA, Staufen, Germany), homogenized and incubated on ice for 5 min in 1 mL of ELISA buffer containing PBS, Triton X-100 (1 mL/mL), PMSF (250 mM in isopropanol, 1 mL/mL), and protease inhibitors (Roche, Mannheim, Germany). Samples were incubated on ice for 20 min, homogenized and centrifuged for 15 min at 48C. TNF-a, IL-1b, and IL-6 were determined in the supernatant using an ELISA technique (R&D Systems, Minneapolis, MN, USA).
Multiplex cytokine assay
Blood was obtained from arterial puncture of the abdominal aortic vessel. Two millilitre syringes were flushed once with 1 mL of heparin (5000 IU/mL). Thereafter, the heparin was removed and blood samples taken. Blood was centrifuged at 3400 g for 10 min and the supernatant (plasma) was stored at 2208C. After thawing, samples were analysed immediately at 378C to facilitate the comparison of results. Levels of TNF-a, IL-1b, and IL-6 (Mouse Cytokine multi-Plex for Luminex TM laser, BioSource Europe) were determined using the microsphere array technique (Luminex 100 system, Luminex Corporatio, Austin, TX, USA) as previously described. 36 
Single-cell experiments 2.2.1 Primary murine cardiomyocytes
Isolation of murine cardiomyocytes was performed as previously described 38 . Cardiomyocytes of WT-and TLR9-D mice were investigated immediately after isolation to determine baseline contractility. Treatment groups were incubated in Dulbecco's modified Eagle medium, supplemented with 5% minimal essential medium, 10% fetal calf serum, 50 mg/mL gentamicin (culture media from Gibco, New York, USA) with and without CpG-ODN (1 mg/mL, equivalent to 0.3 mM according to 27 ) for 1-6 h. In the literature, concentrations for CpG-ODN range from 0.1 to 4 mM. 22, 23, 27, [39] [40] [41] In our experimental setting, this rather low concentration of CpG was sufficient to depress cardiac contractility by 50%. For monitoring the time course of the CpG-ODN effect samples of control cardiomyocytes were taken every hour and the sarcomere shortening was recorded. In our model the maximum effect of CpG-ODN appeared after 5-6 h, therefore WT and TLR9-D cells were investigated at this time point with and without CpG-ODN. To further determine whether depressed cardiac contractility was iNOS dependent, a specific inhibitor of iNOS, S-methylisothiourea (SMT) was applied. Cells were incubated in culture medium supplemented with CpG-ODN (1 mg/mL) for 5-6 h. After 4 h of incubation SMT (100 mM; Sigma-Aldrich, Taufkirchen, Germany) was added and shortenings were recorded as described below.
Single-cell contractility
Sarcomere shortening of ventricular myocytes was recorded with a video imaging system and SarcLen software as published previously (IonOptix, Milton, MA, USA). 17 The regular striation patterns of the sarcomeres were analysed by fast Fourier transformation. The video system is mounted to an inverted microscope (Zeiss Axiovert 135TV, Jena, Germany, lens Fluar 40Â 1.3) and equipped with an experimental chamber with permanent perfusion Tyrode 0 s solution (600 mL/min leading to an exchange rate of three times per minute in the 200 mL volume of the chamber) heated to 368C. Independently of the pretreatment sarcomere shortening was always monitored in Tyrode's solution (in mM: NaCl, 135; KCl, 4; CaCl2, 1.8; MgCl2, 1; Hepes, 2; glucose 10) to avoid direct effects of the incubation media on the contractile response. Contractions were induced by bipolar external stimuli (0.4 ms, 30 V, SD9, Grass, Quincy, MA, USA). Stimuli were applied in pulse trains of 20 stimuli interrupted by a 30 s stimulation pause. The stimulation protocol was: 0.5, 10, 1, 8, 2, 6, 4 Hz.
To obtain representative shortening frequency relationships the five last shortening signals of each train were averaged. The resulting signal was evaluated for the following parameters: resting sarcomere length, amplitude of sarcomere shortening, maximal speed of sarcomere shortening, and re-lengthening. For the demonstration and evaluation of staircases, trains of 20 original recordings of sarcomere shortening of 5-10 cardiomyocytes were averaged. The peak values were fitted by a double exponential function as previously published. 41 
Histology
Histological analysis was performed to document the uptake of fluorescently-labelled oligonucleotides (1668-ODN-Cy5, 1612-ODNCy5; H154-ODN-Cy5) in freshly isolated cardiomyocytes of both genotypes. Coverslips were pretreated with laminin solution (Laminin 10 mg/mL in PBS, L2020 Sigma) for 30 min at room temperature (RT) for adhesion of cardiomyocytes. Cells were stimulated with 1 mg/mL (0.3 mM) 1668-ODN-Cy5 for 30 min at 378C. Further steps were performed at RT. After removal of culture medium cells were fixed for 10 min in freshly prepared 4% paraformaldehyde and permeablized with 0.2% Triton X-100 in PBS for 5 min. After washing (twice with 0.2% Tween in PBS), nuclei were stained with 4 0 -6-Diamidino-2-phenylindole (DAPI) for 30 min. Cells were analysed on an Olympus IX71 inverted microscope (Olympus, Hamburg, Germany).
Statistical evaluation
All values are expressed as mean + SEM. A one-way or two-way ANOVA followed by Bonferroni-corrected post hoc analysis was used when appropriate. For statistical comparison of iNOS-mRNA a t-test was applied. Significant differences were considered to exist at P 0.05.
Results
Clinical manifestations of CpG-ODN challenge
Mice were i.p. sensitized with 1 mg/kg D-GalN. Thirty minutes later, mice received i.p. either 1 nmol/g CpG-ODN, 1 nmol/g non-CpG-ODN or 1 mL/kg saline. In control experiments, D-GalN alone did not induce an inflammatory response (data not shown). Mice were monitored for clinical symptoms. Following 2 h of CpG-ODN challenge, WT mice developed shock-like symptoms such as lethargy and diarrhoea, whereas TLR9-D mice remained healthy. Mice challenged with non-CpG containing oligonucleotides or saline did not exhibit inflammatory signs.
Uptake of CpG-ODN into cardiomyocytes and TLR9 expression
Using fluorescence microscopy, we could demonstrate an uptake of CpG-ODN into freshly isolated cardiomyocytes of both genotypes within 30 min after stimulation ( Figure 1A-D) . However, uptake of CpD-ODN was delayed in TLR9-D cells. CpG-ODN was found in the cytoplasm as well as in the nucleus. Non-CpG-ODN was also tested and its uptake was detected in WT cells (data not shown). The expression of TLR9 in whole myocardial tissue was confirmed by RT-PCR and Western blot analysis. After CpG-ODN challenge the expression of TLR9 demonstrated a timedependent regulation. Figure 1E depicts that TLR9 mRNA was significantly up-regulated after 2 h in comparison to baseline and in comparison to the receptor expression in hearts from TLR9-D mice. The time-dependent TLR9 regulation was also detectable on protein level ( Figure 1F ). Figure 2 illustrates the time course of myocardial NFkB-DNA binding activity following CpG-ODN stimulation. CpG-ODN treatment led to a substantial time-dependent activation (starting at 1 h and lasting up to 4 h) of myocardial NFkB in WT mice. This effect was not detectable in TLR9-D mice. Supershift assays revealed that the NFkB-complex mainly consists of p50 and p65.
NFkB activation in the heart after CpG-ODN stimulation
Myocardial cytokine mRNA and protein expression after CpG-ODN challenge
To determine the contribution of the TLR9 signalling pathway for CpG-induced myocardial cytokine gene expression RNase Protection Assays were performed. Figure 3A -D illustrates the time course of the cytokine mRNA expression of TNF-a, IL-1b, and IL-6 following CpG-ODN administration. CpG-ODN induced a rapid and robust increase in TNF-a, IL-1b, and IL-6 mRNA transcripts in hearts of WT mice. Peak cytokine expression was detected 1-2 h after injection of CpG-ODN. Densitometric analysis ( Figure 3B-D) revealed a significant increase in the expression of the above mentioned cytokines in WT mice. This effect was not detectable in TLR9-D animals. In addition, the inflammatory response of various control oligonucleotide sequences (ODN 1612, ODN H154) was analysed indicating no significant up-regulation of cytokine gene mRNA in the heart ( Table 1) . To determine a direct relationship between increased mRNA expression and protein content in the heart, we carried out ELISAs. Figure 4 illustrates that CpG-ODN administration led to a significant increase in protein expression of TNF-a, IL-1b, and IL-6 in myocardial tissue from WT mice. A strong increase in cytokine production was observed after injection of CpG-ODN with a peak protein expression at 1 h for TNF-a (5 Â fold) and at 2 h for IL-1b (5 Âfold) and IL-6 (7 Â fold). This effect was not detectable in TLR9-D animals.
Plasma cytokine levels following systemic CpG-ODN challenge
CpG-ODN-treated WT animals showed a significant increase in the plasma levels of the cytokines TNF-a and IL-6 after 2 h. Plasma levels of IL-1b increased much less after 2 h without reaching statistical significance. These effects were not detectable in CpG-ODN-treated TLR9-D mice. After 6 h, cytokine levels in WT mice returned to baseline levels ( Figure 5 ).
Influence of CpG-ODN on sarcomere shortening
Sarcomere shortening of isolated ventricular cardiomyocytes from WT and TLR9-D mice was monitored in order to investigate whether CpG-ODN affects cardiomyocyte shortening and whether these changes are mediated via TLR9. Amplitude of sarcomere shortening from WT and TLR9-D cardiomyocytes depended on stimulation frequency. After a stimulation pause the first shortening is characterized by a high amplitude (post-rest shortening). Subsequently, the post-rest shortening is followed by a negative staircase at low frequencies (,6 Hz) and a positive staircase at high frequencies (.6 Hz) ( Figure 6 ). This contractility pattern was similar in cardiomyocytes from WT and TLR9-D mice. Treatment of WT cells with CpG-ODN for .4 h depressed both post-rest and steady-state shortening. However, neither frequency-dependent shortening behaviour nor resting sarcomere length was influenced by CpG-ODN. A detailed analysis of the time course of CpG-ODN effects exhibits a tendency to decreased shortenings 3 h after the start of treatment and reaches the level of significance after 4 h ( Figure 7A) .
In plots of steady-state shortening amplitude vs. stimulation frequency shortening amplitude exhibits a biphasic pattern with a negative shortening-frequency relationship ,2 Hz and a positive relationship .2 Hz. At 2 Hz shortening was minimal ( Figure 7B ). This pattern was comparable in both WT and TLR9-D cells ( Figure 7C) . Six hours of cell culture did not change this pattern of contractility nor did it alter the shortening amplitudes ( Figure 7B) . Addition of CpG-ODN induced a significant decrease of shortening amplitude in WT cells at all frequencies ( Figure 7B and D) , whereas in TLR9-D cells shortening amplitude was insensitive to CpG-ODN treatment ( Figure 7C ). The speed of sarcomere shortening as well as re-lengthening showed the same frequency relationship as the sarcomere-shortening amplitude, and in WT cells CpG-ODN suppressed both parameters significantly (data not shown). In a second set of experiments the influence of iNOS inhibition on CpG-ODNdependent suppression of myocyte shortening was tested ( Figure 7D ). In these experiments steady-state shortening amplitude was significantly reduced at all tested frequencies. Addition of SMT, a selective iNOS blocker, during the last hour of CpG-ODN treatment reversed the reduction of shortening completely.
Myocardial iNOS mRNA expression
We compared myocardial iNOS mRNA expression after CpG-ODN challenge in WT and TLR9-D mice. CpG-ODN application caused a pronounced induction of iNOS mRNA expression in WT compared with TLR9-D mice ( Figure 7E and F) .
DISCUSSION
Cardiac depression is a serious and frequent complication of human sepsis. Several mechanisms have been postulated for Table 1 Influence of three different oligonucleotides (1668, H154, 1612) on cardiac mRNA of TNF-a, IL-6, and IL-1b detected 2, 4, and 6 h after injection into WT mice. The oligonucleotide 1668 caused an increase of all cytokine mRNA, whereas the other two oligonucleotides did not induce significant increases (*P , 0.05 compared with respective control values; n ¼ 3-5/time point) the impaired myocardial function during sepsis including accumulation of (i) bacterial wall fragments like LPS, 42 (ii) various cytokines such as IL-1b and TNF-a 9 , and (iii) reactive oxygen/nitrogen species. 43, 44 Altered NO production within the heart is believed to participate in the pathogenesis of heart failure originated from sepsis. 11 There is good evidence that the endocrine, immune, and nervous system are in concert to depress cardiac contractility under inflammatory conditions. This has led to the new concept that innate immunity, i.e. the TLR system may play an important role in this scenario. We have previously shown that TLR4-as well as CD14-deficiency abolishes LPS-induced contractile dysfunction in vivo. 15, 16, 18 In a similar experimental setting we could also demonstrate that Staphylococcus aureus mediates cardiac dysfunction via TLR2. 19 Bacterial DNA (CpG-ODN) can initiate an innate immune response via TLR9 potentially leading to septic shock. 22, 23 TLR9 is localized in the endoplasmatic reticulum and following CpG stimulation recruited to endosomal vesicles. 45, 46 Then, TLR9 and CpG-ODN co-localize resulting in cell activation. Ligand-binding studies showed that bacterial DNA binds directly to TLR9. Following CpG-ODN binding, TLR9 associates with the adaptor molecule MyD88 resulting in activation of the IL-1 receptor-associated kinase family and mitogen-activated protein kinases. The latter events Plasma levels of TNF-a and IL-6 were significantly increased after 2 h. Plasma levels of IL-1b were elevated after 2 h without reaching statistical significance (*P 0.05, n ¼ 5).
activate NFkB among other transcription factors (for detailed review please ref. 47) .
Little is known about the role of TLR9 in the myocardium, but constitutive TLR9 expression levels have been detected in the heart. 29, 30, 48 Our study demonstrates a TLR9-dependent mechanism of cardiac inflammation in vivo (i.p. application 1 nmol/g BW), which was absent in TLR9-D animals. After incubation with 1 mg/mL CpG-ODN, cardiomyocyte contractility in vitro was reduced in WT-and unaffected in TLR9-D cells. Despite the fact that various papers suggest similar in vivo and in vitro doses for CpG-ODN, it is unclear whether these concentrations correlate with the clinical setting in vivo. Preliminary data shown in the methods section demonstrate that 20 nmol in vivo is a saturating dose on the cytokine expression in murine pulmonary tissue. So far, levels of CpG-ODN in tissue have not been reported in the literature. In the clinical setting of sepsis this question is even harder to answer since the amplification of short fragments derived from bacterial DNA is technically difficult. At this point amplification of bacterial products is used to identify different bacteria, but we are not aware of an experimental approach quantifying bacteria or bacterial products. Our data are in accordance with others that TLR9 mRNA is expressed in homogenates of cardiac tissue. 29, 30, 34, 48, 49 Furthermore, we demonstrated intracellular as well as nuclear incorporation of fluorescence-labelled 1668-ODN-Cy5 into isolated cardiomyocytes of both genotypes within 30 min of treatment indicating that CpG-ODN is internalized to interact with the receptor. InternaIization of ODNs seems to be independent of the presence of TLR9 as well as independent of the presence of the CG motif. This observation is consistent with previous reports indicating that CpG-ODNs appear to be sequence-independently endocytosed into glioblastoma cells. 50 However, uptake of 1668-ODN-Cy5 in TLR9-D cells was slower. In addition, CpG-ODN led to a significant time dependent up-regulation of TLR9 mRNA and protein in WT mice ( Figure 1E and F) . It is known that TLR9 stimulation leads to the activation of NFkB in various tissues. 47, 51 However, we show for the first time that also cardiac NFkB activity is up-regulated following CpG-ODN application. Constitutive expression of TLR9 seems to be responsible for NFkB activation and cytokine induction as well as the increase in TLR9 expression (at 2 h). TLR9 up-regulation may not lead to further NFkB activation/cytokine induction because the injected CpG-ODN may already have been degraded after 2 h.
In WT mice, CpG-ODN led to a significant increase of TNF-a, IL-1b, and IL-6 mRNA and protein expression in the heart. TNF-a mRNA did not clearly precede the respective protein expression. This observation may be related to the low time resolution of 1 h. However, in case of IL-1b and IL-6 mRNA expression rises earlier than protein expression. Furthermore, increased plasma levels of TNF-a, IL-1b, and IL-6 indicate systemic inflammation in WT animals. In contrast, the level of these cytokines did not change in TLR9-D mice after CpG challenge.
In our study cardiac contractility measured as sarcomere shortening of isolated cardiomyocytes from WT-and TLR9-D mice was recorded at stimulation frequencies between 0.5 and 10 Hz after incubation with 1 mg/mL CpG-ODN for up to 6 h. Treatment for .4 h depressed both post-rest and steady-state shortening. Detailed analysis of the time course of CpG-ODN effects exhibited tendency to decreased shortenings 3 h after the start of treatment reaching statistical significance after 4 h. As iNOS levels and cardiomyocyte contractility are linked, we investigated whether iNOS was regulated via TLR9 in vivo. CpG-ODN application caused a pronounced induction of iNOS mRNA in WT compared with TLR9-D mice ( Figure 7E and i) . Inhibition of iNOS with SMT prevented CpG-ODN-mediated effects on shortening in the current study, and this suggests that iNOS and NO are relevant members of the TLR9 signalling cascade within cardiomyocytes.
A study by Paladugu et al. 52 reported that bacterial DNA (from S. aureus and Escherichia coli) depressed myocardial contraction in rat neonatal cardiomyocytes in a concentration-dependent fashion, ranging from 43-61%. Since pretreatment with DNase led to abrogation of depression of myocyte contraction, the observed myocyte contraction depression was attributed to the ligand itself and not potential contaminating proteins. On one hand, this study supports our data indicating that bacterial DNA has the potential to depress cardiac contractility. On the other hand, these authors have not examined whether this effect was mediated by a specific receptor, particularly by TLR9. Furthermore, it is unclear whether the TLR9 expression pattern might change from neonatal to adult cells. Therefore, our data demonstrate for the first time that bacterial DNA depresses cardiac contractility via myocardial TLR9.
Whether other TLR ligands (e.g. LPS) directly act on cardiomyocytes or function via the presence of leukocytes remains controversial. 17, 53 Since contractility studies were performed in pure cardiomyocyte cultures, our results indicate that this effect can be attributed to cardiomyocytes alone and that cardiomyocytes might have the potential to recognize pathogenic ligands via TLRs. In addition, cardiomyocytes have the capability to produce inflammatory and cardiac depressive mediators, including TNF-a and NO supporting the fact that ligand-mediated effects on sarcomere shortening occur in absence of immune cells. 8, 54 Recently, Boyd et al. 30 reported that cognate ligands of TLR2, 4, and 5 induced mediator production in the conditioned media of a murine cardiomyocyte cell line (HL-1 cells) 24 h after stimulation. The fact that TLR2, 4, and 5 activation can lead to cytokine induction in the heart has been reported before, generally documenting cytokine production within 2-6 h after stimulation using the respective pathogenic ligand. 15, 17, 19, 20 In contrast to our study, Boyd et al. 30 reported that stimulation with CpG-ODN for 24 h did not lead to cytokine (IL-6) and chemokine (KC, MIP-2) production. These differences might be due to the HL-1 cell line itself or to the long duration of stimulation (24 h). In addition, the most important mediators for cardiac depression during sepsis (TNF-a, IL-1b) were not determined. Figures 3 and 4 indicate that CpG-ODN induces maximal cytokine production within 1-2 h of stimulation. This is in context with our observation that WT mice showed clinical symptoms of inflammation 2 h following CpG-ODN stimulation.
We propose that bacterial DNA causes myocardial dysfunction. The fact that spontaneous or drug-induced bacterial degradation eventually leads to the liberation of bacterial DNA has not been taken into consideration yet in respect to ligand-induced organ dysfunction. Furthermore, our results demonstrate that the presence of immune cells is not essential for TLR9-mediated myocardial depression.
